Prognostic Value of Plasma Biomarkers Among Patients With Hypertension

Beijing Institute of Heart, Lung and Blood Vessel Diseases1 site in 1 country600 target enrollmentApril 1, 2017

ConditionsHypertension

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Hypertension
Sponsor: Beijing Institute of Heart, Lung and Blood Vessel Diseases
Enrollment: 600
Locations: 1
Primary Endpoint: Primary mortality of hypertension
Last Updated: 6 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

Hypertension is the most important risk factor for cardiovascular and cerebrovascular diseases，and also a substantial public health problem. The purpose of the study is to investigate the association between plasma biomarkers and adverse outcomes in patients with hypertension.

Registry

clinicaltrials.gov

Start Date

April 1, 2017

End Date

August 2022

Last Updated

6 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Beijing Institute of Heart, Lung and Blood Vessel Diseases

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•\>18 years old
•In accordance with the diagnosis of hypertension (BP≥140/90mmHg)

Exclusion Criteria

•The exclusion Criteria for the study program were as follows:
•Pregnancy, history of heart failure or left ventricular ejection fraction less than 40%, myocardial infarction within one month, percutaneous transluminal coronary angioplasty or coronary artery bypass grafting, cerebrovascular disease, severe liver disease, severe chronic renal failure (eGFR less than 30 mL/min/1.73 m2) in the past three months.